Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-low-do...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, William A.E., Orme, Rachel C., Hanson, Jessica, Stokes, Hannah M., Bridge, Claire M., Shaw, Patricia A., Sumaya, Wael, Thorneycroft, Kirstie, Petrucci, Giovanna, Porro, Benedetta, Judge, Heather M., Ajjan, Ramzi A., Rocca, Bianca, Storey, Robert F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Plenary Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425913/
https://www.ncbi.nlm.nih.gov/pubmed/30759035
http://dx.doi.org/10.1080/09537104.2019.1572880

Ejemplares similares

Ejemplares similares